Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects
NCT04283097
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
Scientists are conducting a study to test the safety and effectiveness of a medicine called KPG-818. They will give it to adults with a type of cancer called multiple myeloma along with another medicine called dexamethasone. They will also test KPG-818 alone in adults with other types of cancer, like mantle cell lymphoma and chronic lymphocytic leukemia. The study is the first step in finding out how much of the medicine people can take without getting sick, so that they can conduct more studies in the future.
Scientists are conducting a study to test the safety and effectiveness of a medicine called KPG-818. They will give it to adults with a type of cancer called multiple myeloma along with another medicine called dexamethasone. They will also test KPG-818 alone in adults with other types of cancer, like mantle cell lymphoma and chronic lymphocytic leukemia. The study is the first step in finding out how much of the medicine people can take without getting sick, so that they can conduct more studies in the future.
Third Opinion AI Generated Synopsis
Trial Summary
This is a phase 1, multicenter, open-label, multiple-ascending dose study to evaluate the safety, pharmacokinetics and clinical activity of KPG-818 in subjects with hematological malignancies. Approximately 30 patients will be enrolled for dose escalation of 4 dose levels. Indication: Hematological malignancies (multiple myeloma \[MM\], mantle cell lymphoma \[MCL\], diffuse large B-cell lymphoma \[DLBCL\], adult T-cell leukemia-lymphoma \[ATL\], and indolent non Hodgkin lymphomas such as follicular lymphoma \[FL\] and chronic lymphocytic leukemia \[CLL\]/small lymphocytic lymphoma \[SLL\]).
This is a phase 1, multicenter, open-label, multiple-ascending dose study to evaluate the safety, pharmacokinetics and clinical activity of KPG-818 in subjects with hematological malignancies. Approximately 30 patients will be enrolled for dose escalation of 4 dose levels. Indication: Hematological malignancies (multiple myeloma \[MM\], mantle cell lymphoma \[MCL\], diffuse large B-cell lymphoma \[DLBCL\], adult T-cell leukemia-lymphoma \[ATL\], and indolent non Hodgkin lymphomas such as follicular lymphoma \[FL\] and chronic lymphocytic leukemia \[CLL\]/small lymphocytic lymphoma \[SLL\]).
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
